OSSFF OTC
Embla Medical hf.
1W: +0.0%
1M: -0.4%
3M: +9.2%
YTD: -14.8%
1Y: -5.6%
3Y: -11.2%
5Y: -37.5%
$4.53
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$932M
+9.0% ▲
5Y CAGR: +8.2%
Gross Profit
$542M
+8.4% ▲
5Y CAGR: +8.5%
Operating Income
$125M
+11.0% ▲
5Y CAGR: +18.3%
Net Income
$84M
+22.5% ▲
5Y CAGR: +68.2%
EPS (Diluted)
$0.20
+25.0% ▲
5Y CAGR: +68.6%
EBITDA
$184M
+9.4% ▲
5Y CAGR: +20.8%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $719M | $719M | $786M | $855M | $932M |
| YoY Growth | +14.2% | -0.0% | +9.3% | +8.8% | +9.0% |
| Cost of Revenue | $298M | $311M | $331M | $355M | $390M |
| Gross Profit | $421M | $408M | $454M | $500M | $542M |
| Gross Margin | 58.6% | 56.8% | 57.8% | 58.5% | 58.2% |
| R&D Expenses | $27M | $29M | $33M | $35M | $40M |
| SG&A Expenses | $299M | $293M | $334M | $352M | $378M |
| Operating Expenses | $325M | $323M | $367M | $387M | $417M |
| Operating Income | $96M | $85M | $87M | $113M | $125M |
| Operating Margin | 13.3% | 11.8% | 11.1% | 13.2% | 13.4% |
| Interest Expense | $13M | $13M | $21M | $25M | $21M |
| Income Before Tax | $87M | $56M | $76M | $91M | $108M |
| Tax Expense | $21M | $13M | $17M | $22M | $24M |
| Net Income | $64M | $43M | $58M | $68M | $84M |
| Net Margin | 8.9% | 5.9% | 7.4% | 8.0% | 9.0% |
| EPS (Diluted) | $0.15 | $0.10 | $0.14 | $0.16 | $0.20 |
| EBITDA | $151M | $118M | $143M | $168M | $184M |
| Shares Outstanding | 423M | 418M | 420M | 427M | 427M |